TY - JOUR
T1 - Therapeutic treatment of canine osteoarthritis with glycosaminoglycan polysulfuric acid ester
AU - Altman, Roy D.
AU - Dean, David D.
AU - Muniz, Ofelia E.
AU - Howell, David S.
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1989/10
Y1 - 1989/10
N2 - The therapeutic effect of glycosaminoglycan polysulfuric acid ester (GAGPS) was studied using the Pond‐Nuki model of canine osteoarthritis. The clinical setting was simulated by permitting 4 weeks ambulation without treatment, following anterior cruciate transection. Animals were then injected with GAGPS, 4 mg/kg intramuscularly, twice weekly during weeks 4–8. Control animals received intramuscular saline. The study was terminated 4 weeks after completion of the GAGPS or saline regimen (i.e., 12 weeks postoperatively). Cartilage from the medial femoral condyle was analyzed for collagen integrity (swelling properties), hydroxyproline, uronic acid, active and total proteoglycan (PG)–degrading metalloproteinase, PG‐degrading serine proteinase, and histopathology (Mankin score). Condylar cartilage from animals treated with GAGPS demonstrated less cartilage swelling, less total and active metalloproteinase, and lower histopathologic scores than were found in cartilage from saline‐treated animals. GAGPS was able to suppress PG‐degrading enzyme activity and maintain a more normal‐appearing cartilage. It is proposed that GAGPS suppressed PG breakdown by decreasing synthesis of metalloproteinase or by directly inhibiting metalloproteinase in cartilage, rather than by increasing synthesis of PG by chondrocytes.
AB - The therapeutic effect of glycosaminoglycan polysulfuric acid ester (GAGPS) was studied using the Pond‐Nuki model of canine osteoarthritis. The clinical setting was simulated by permitting 4 weeks ambulation without treatment, following anterior cruciate transection. Animals were then injected with GAGPS, 4 mg/kg intramuscularly, twice weekly during weeks 4–8. Control animals received intramuscular saline. The study was terminated 4 weeks after completion of the GAGPS or saline regimen (i.e., 12 weeks postoperatively). Cartilage from the medial femoral condyle was analyzed for collagen integrity (swelling properties), hydroxyproline, uronic acid, active and total proteoglycan (PG)–degrading metalloproteinase, PG‐degrading serine proteinase, and histopathology (Mankin score). Condylar cartilage from animals treated with GAGPS demonstrated less cartilage swelling, less total and active metalloproteinase, and lower histopathologic scores than were found in cartilage from saline‐treated animals. GAGPS was able to suppress PG‐degrading enzyme activity and maintain a more normal‐appearing cartilage. It is proposed that GAGPS suppressed PG breakdown by decreasing synthesis of metalloproteinase or by directly inhibiting metalloproteinase in cartilage, rather than by increasing synthesis of PG by chondrocytes.
UR - http://www.scopus.com/inward/record.url?scp=0024438241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024438241&partnerID=8YFLogxK
U2 - 10.1002/anr.1780321016
DO - 10.1002/anr.1780321016
M3 - Article
C2 - 2803328
AN - SCOPUS:0024438241
VL - 32
SP - 1300
EP - 1307
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
SN - 2326-5191
IS - 10
ER -